Highlights

  • Ceryvyn is concentrating its drug development programme on lymphangioleiomyomatosis, a rare lung disease.
  • CYV-101 is being developed as an inhaled formulation targeting VEGF-C and VEGF-D signalling.
  • FY26 reported profit was primarily attributable to a one-off accounting gain rather than operating earnings.
  • The company finished June 2026 with A$30.0 million in cash and equivalents.
  • Preclinical work, development costs and regulatory requirements remain central uncertainties.

Ceryvyn Therapeutics Limited (ASX:CYV) is an Australian biotechnology company developing CYV-101, a biologic therapy aimed at lymphangioleiomyomatosis (LAM), a rare disease affecting the lungs. The company has repositioned its development priorities during 2026, concentrating resources on an inhaled formulation and reporting a substantially changed financial position for the year ended 30 June 2026.

A New Direction for CYV-101

Ceryvyn Therapeutics Limited (ASX:CYV) is developing CYV-101 to bind the growth factors VEGF-C and VEGF-D, which are involved in signalling through the VEGFR-3 pathway. The proposed approach targets abnormal lymphatic activity associated with LAM. Its intended delivery method is nebulisation, allowing the therapy to be inhaled rather than administered through a conventional systemic route.

The company describes its work as a staged development programme. Feasibility and inhalation studies form part of the early evaluation, while later clinical decisions depend on scientific findings and available capital. The biological rationale has not yet established clinical efficacy for LAM, and the product is not an approved therapy for the disease.

During 2026, the business also changed its corporate identity from Opthea Limited. The company name took effect in July and trading under the code (ASX:CYV) began on 9 July 2026, following shareholder approval.

What the FY26 Accounts Show

For the year ended 30 June 2026, Ceryvyn Therapeutics Limited (ASX:CYV) reported a profit after tax of A$330.4 million. That result included a A$357.1 million gain on derecognition of a development funding agreement. The gain was an accounting consequence of the agreement’s settlement, not revenue generated by commercial sales of a therapy.

The operating loss was approximately A$11.9 million. This difference matters because the statutory profit cannot be treated as evidence of recurring operating profitability. The company continues to incur costs while advancing research, and it has no approved product generating commercial revenue.

At 30 June 2026, cash and equivalents were A$30.0 million, compared with A$31.2 million at 31 March 2026. The annual report recorded net assets of A$29.6 million and no debt at the reporting date.

Research Spending and Development Conditions

Ceryvyn Therapeutics Limited (ASX:CYV) recorded research and development expenses of A$13.127 million and administration and corporate costs of A$7.499 million in FY26. Government grants and tax incentives totalled A$10.968 million, while net operating cash outflow was A$12.5 million. These figures illustrate the distinction between financing a development programme and earning recurring product revenue.

The company has also sought intellectual property protection for inhaled VEGF-inhibitor treatments, including an application relating to pulmonary diseases. Additional preclinical evidence, manufacturing preparation and regulatory engagement would be needed before any intended treatment could progress further.

For (ASX:CYV), the timing and overall cost of later development stages remain uncertain. Funding arrangements, technical results and regulatory decisions may affect how the programme proceeds. The company has additionally identified uncertainty around the availability of research and development rebates beyond FY27.

Key Insights

Ceryvyn Therapeutics Limited (ASX:CYV) has moved toward a more concentrated rare-disease research strategy following its 2026 corporate reset. Its FY26 accounts show that the large statutory profit arose mainly from a non-recurring financial adjustment, while operational expenditure and clinical development requirements remain relevant. Cash resources, the quality of preclinical evidence and the steps needed to progress CYV-101 provide the principal factual context for assessing subsequent company disclosures.